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Abstract
Background: The incidence of detected ductal carcinoma in situ (DCIS) continues to
increase and now accounts for 14% of all breast cancer, and 20%–25% of screen-detected
cases. Treatment trends of DCIS are important in order to inform the ongoing debate about
possible overdiagnosis and overtreatment, but have not been investigated for over a decade
in Australia and New Zealand. Against this background, we aimed to describe the temporal
trends in management of DCIS in Australian and New Zealander women.
Methods: Using the BreastSurgANZ Quality Audit (BQA) database, we conducted a
descriptive study of the trends of management of DCIS in Australia and New Zealand from
2007 to 2016. We assessed the frequency of surgical treatments, adjuvant therapies, and
axillary surgery conducted in women with pure DCIS.
Results: There were 17 883 cases of pure DCIS in 2007–2016 in Australia and New Zealand
recorded in the BQA database. The treatment patterns were consistent with no changes over
time. The most common surgical treatment was breast-conserving surgery (66%), followed by
mastectomy (37%), and 36% of women with DCIS received sentinel node biopsy (SNB).
Conclusion: The clinical management of women diagnosed with DCIS in Australia and
New Zealand, appears stable over time. A substantial proportion of women with DCIS
receive SNB and this aspect of surgical care warrants further exploration to determine
whether it represents appropriate care. These results, alongside the outcomes of the ongoing
clinical trials on the management of DCIS, will help inform if any changes to best practice
treatment are required.
Introduction
DCIS, ductal carcinoma in situ, indicates an abnormal growth of
epithelial cells within breast ducts and lobules.1 Unlike invasive
breast cancer, DCIS does not invade surrounding tissue or spread to
other places of the body and long term mortality is low.2 Together
with small, invasive breast cancer, DCIS may be categorized as early
breast cancer and is notifiable to Australian cancer registries.3
Mammographic screening aims to find breast cancer at an early
stage to decrease breast cancer mortality, as well as improve surgical
outcomes and reduce unnecessary treatment.4 Since the introduction
of breast cancer screening programs, mammography has detected
more DCIS due to the visible characteristic calcifications,3,5,6
(Fig. 1). DCIS was considered rare prior to the introduction of
screening. In contrast, today, DCIS makes up about 20%–25% of the
screen-detected cancers,4–7 and 14% of all breast cancer.3 In addi-
tion, mammographic screening has become more sensitive due to the
improvements in technology. These step-wise advances have seen
analog film replaced by digital mammography and 3D mammogra-
phy (tomosynthesis), and commensurate with the practice shift, the
majority of the increased detection has been in screen-detected
DCIS.3 As such, DCIS rates continue to rise in Australia.3
The national breast screening program in Australia, BreastScreen
Australia, started in 1991.8 Mammographic screening in Australia
is recommended every 2 years for women aged 50–74.9 In
Australia, women receive invitations to attend screening when they
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turn 50 years of age; however, women can attend screening starting
at age 40. Screening may be recommended to women before age
50 if they are at a greater risk of breast cancer.9 The biennial
screening program in New Zealand, BreastScreen Aotearoa, was
rolled out nationwide in 1998.10 In 2004, the age range of
BreastScreen Aotearoa was extended from 50–64 to 45–69 years
old, nearly doubling the number of women being screened each
year.10
Overdiagnosis of breast cancer occurs when mammography
screening leads to the detection of a cancer that would never have
presented clinically if the woman had not been screened.11,12 Over-
diagnosis may lead to overtreatment. Concerns about overtreatment
of DCIS have led to the establishment of several trials of treatment
de-escalation for low-risk DCIS4,5,11 to investigate active monitor-
ing as an alternative to surgery.5,6,13
In current clinical practice, however, surgery remains the main-
stay of clinical management of DCIS, pending results of the de-
escalation trials. Furthermore, in contrast to invasive breast cancer,
surgical guidance for treatment of DCIS is limited or lacking and as
such it is unclear to what extent variation in surgical practice may
exist currently in Australia and NZ.
Against this background it is timely to analyze patterns of surgi-
cal treatment of DCIS, examining temporal trends over the past
decade. The most recent analysis of DCIS management in Australia
and New Zealand was conducted more than a decade ago and, as
such, we considered an updated analysis would be informative.14
The aim of this study therefore was to describe temporal trends in
the management of DCIS of the breast in Australian and
New Zealand women over the decade 2007–2016.
Methods
Study design
We conducted a retrospective study using data sourced from a
clinical breast cancer database, the BreastSurgANZ Quality
Audit (BQA). Surgeons, members of the specialist society,
Breast Surgeons of Australia and New Zealand, contribute to this
database to capture data on the management and treatment of
breast cancer.15 The study was approved by HUMAN
RESEARCH ETHICS COMMITTEE at Sydney University, pro-
ject number 2019/086.
DCIS episodes were available from the start of the collection in
1998 through end of 2018. We used only episodes where the histol-
ogy report showed pure DCIS, excluding any type of invasive
breast cancer. We measured the capture rate of the BQA data for
both Australia and New Zealand by comparing reported cases of
DCIS to the national cancer registries in both countries, AIHW and
Ministry of Health NZ.8,14,16 We set an a priori threshold for ade-
quate capture at 60%, that is at least 60% of DCIS registered on
cancer registries were included in the BQA dataset for that year.
The years 2007–2016 were the most recent 10-year period with a
capture rate for all years for both countries above our a priori cutoff
of 60%. An episode in the database is defined as the diagnosis and
treatment period for a woman with DCIS. Women who had more
than one episode recorded either had more than one primary tumor
site, or a DCIS recurrence 3 months after surgery with clear mar-
gins. Only the first episode for each woman was included in order
to avoid over-counting of a single woman’s treatment experi-
ence. (Fig. 2).
Fig 1. Ductal carcinoma in situ (DCIS) visible on the mammogram in the upper part of the left breast as an area with polymorphic calcifications with a lin-
ear/branching arrangement following the ducts (magnification, top right). The histological image, bottom right, clearly shows the cancer is confined within
the basal membrane (black arrows), with necrotic cells in the center of the duct (white arrow). The necrotic areas calcify and give rise to the characteristic
mammography image (Image courtesy, Skåne University Hospital Malmö).
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Data analysis
We combined records from Australia and New Zealand, acknowl-
edging that contributing members from both jurisdictions are
required to submit their total caseload to the audit and are
benchmarked by the same key performance indicators. We mea-
sured time trends of the type of surgery, adjuvant therapy, and axil-
lary surgery conducted using descriptive statistics. Surgery and
treatment included: mastectomy, breast-conserving surgery (BCS),
open biopsy, re-excision, reconstruction, no surgery, radiotherapy,
tamoxifen, sentinel node biopsy (SNB), axillary surgery (i.e. level
1, 2, or 3 axillary lymph node dissection), and no axillary surgery.
Additionally, we stratified data by patient age, menopausal status,
histological grade of the tumor, and tumor size based on histopa-
thology. Chi-squared analysis was used to test significance between
subgroups and the Mantel–Haenszel method was used to test for
trend over time (SAS 9.4).
Results
Study population and characteristics of women
with DCIS
A total of 17 883 cases of DCIS were recorded in the BQA data-
base in Australia and New Zealand from 2007 to 2016; 14 278
cases (overall capture rate 69%) from Australia and 3925 cases
(overall capture rate 78% New Zealand) (Table 1).
In both countries, the highest percentages of women diagnosed
with DCIS were among women aged 50–69 years. DCIS was more
common among women aged 40–49 in New Zealand than in
Australia. Conversely, among women aged 70–74 years, DCIS was
more common in Australia than in New Zealand. Most of the
women diagnosed with DCIS in New Zealand were diagnosed and
treated in the public health care system (66.0%), while in Australia
more women were treated privately (62%). The most common
referral source was from screening programs (57.8%). The
remaining women were either symptomatic (29.1%), that is, they
were referred to the breast surgeon after presenting to a GP or other
physician, or were referred from other sources (13.1%) including
private screening. Most cases were among postmenopausal women,
although a sizeable minority (19–28%) was premenopausal (higher
in New Zealand). Most cases were intermediate or high-grade his-
tology, and ≤20 mm.
Surgical procedures
The most common type of surgery was BCS (65.5%, mastectomy
36.6%). Open biopsy was conducted among 12.3%, re-excision in
18.2% and reconstruction in 12.6% of women. Of women who had
a mastectomy, 33.4% had reconstruction. Less than 1% of women
(0.4%) did not undergo any form of surgery (n = 74).
Rates of surgical procedures were generally stable over time
(Fig. 3), except for SNB which increased (described in detail
below). Small fluctuations over time were statistically significant
for all the surgical procedures except for reconstruction and no sur-
gery (for which fewer events occurred) but are not of clinical
significance.
Axillary procedures
SNB was conducted among 36.0% of women. An increase in SNB
was observed over time: 27.5% of women had SNB in 2007, com-
pared to 36.2% in 2016 (p < 0.0001) (Table 2, Fig. 3). Women with
high-grade DCIS had the highest frequency of SNB (44.9%),
whereas a smaller percentage of women with intermediate-grade
(29.8%) and low-grade (19.6%) DCIS had SNB. Among women
who had a mastectomy, 71.2% had a SNB, whereas 18% of
women who had BCS also had SNB (Table S1). Of women with
tumor size less than or equal to 20 mm, 16.1% had SNB compared
to 21.4% of women with tumors greater than 20 mm. (Table 3).
Axillary lymph node dissection (ALND) was performed in 4.1%
of women, with a slight decrease over time: 7.1% of the women
with DCIS had ALND in 2007, while 2.9% of the women had
ALND in 2016 (p < 0.0001) (Table 2). Of the ALND performed,
11.2% had positive axillary lymph nodes (n = 82).
Variation in surgical procedures by women’s
and tumor characteristics
Statistically significant differences were observed according to age,
histological grade, tumor size, and menopausal status (Table 3).
Age was consistently associated with differences in treatment
options. Most women aged 15–39 underwent mastectomy (62.4%),
while fewer women aged 40–49 years (46%) and over 50 years
(<40%) had mastectomy, while the opposite trend was observed
for BCS. Immediate reconstruction was more commonly per-
formed among younger women diagnosed with DCIS (15–39,
36.2%, 40–49, 25.4%), and it decreased steadily with age. More
women in the younger age groups (15–39, 53.9%, 40–49,
Fig 2. Flow chart of inclusions and exclusions of women with DCIS (duc-
tal carcinoma in situ) in our study.
© 2021 The Authors.
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42.3%) had SNBs, compared to women 50 and older (30–35%)
(Table 3). Patterns according to menopausal statuses reflected
those for age.
Women with high-grade DCIS were more likely to be treated by
mastectomy and were more likely to undergo SNB. The majority of
women, 53.3% with a DCIS lesion greater than 20 mm, had a SNB and
58.0% (n = 4453) had a mastectomy. Among women with a tumor size
less than or equal to 20 mm, 23.2% (n = 2239) had a SNB conducted
and 20.1% (n = 1940) had a mastectomy.
Women who had a mastectomy were more likely to have a SNB
and/or an open biopsy than women who had BCS, whereas more
women who had BCS had a re-excision (Table S1).
Adjuvant therapies
Themost common adjuvant therapywas radiotherapy (42.0%). Ofwomen
who had BCS, 64.9% had radiotherapy. Tamoxifen was used among
8.4%ofwomen andAromatase inhibitors in 5.1%ofwomen (Table S2).
Discussion
Summary of main findings
The majority (60%) of DCIS cases were among women aged 50–
69 years, consistent with screening mammography programs
Table 1 Descriptive characteristics of women with DCIS
New Zealand, n = 5016 Australia, n = 20 723 Total, n = 17 883
Age
15–39 84 (2.2) 413 (3.0) 497 (2.8)
40–49 886 (22.8) 2125 (15.2) 3011 (16.8)
50–59 1281 (33.0) 4330 (30.9) 5611 (31.4)
60–69 1188 (30.6) 4573 (32.7) 5761 (32.2)
70–74 205 (5.3) 1410 (10.1) 1615 (9.0)
75-highest 237 (6.1) 1151 (8.2) 1388 (7.8)
Private 1320 (34.1) 8326 (62.2) 9646 (55.9)
Public 2557 (66.0) 5055 (37.8) 7612 (44.1)
State
NSW 4134 (29.6) 4134 (23.1)
QLD 3226 (23.1) 3226 (18.1)
NT 40 (0.3) 40 (0.2)
SA 1295 (9.3) 1295 (7.3)
WA 1582 (11.3) 1582 (8.9)
TAS 229 (1.6) 229 (1.3)
VIC 3197 (22.3) 3197 (17.9)
ACT 281 (2.0) 281 (1.6)
NZ 3881 (100) 3881 (21.7)
Referral source†
Symptom 773 (20.0) 4389 (31.6) 5162 (29.1)
Breast screen 2533 (65.6) 7722 (55.7) 10 255 (57.8)
Other 556 (14.4) 1759 (12.7) 2315 (13.1)
Menopausal status
Premenopausal 1067 (28.3) 2636 (19.0) 3703 (21.0)
Postmenopausal 2348 (62.2) 10 011 (72.3) 12 359 (70.1)
Perimenopausal 361 (9.6) 1203 (8.7) 1564 (8.9)
Histological grade
Low 557 (14.7) 1780 (13.4) 2337 (13.7)
Intermediate 1406 (37.1) 4199 (31.6) 5605 (32.8)
High 1824 (48.2) 7323 (55.1) 9147 (53.5)
Tumor size‡
≤20 mm 2199 (58.0) 7467 (55.1) 9666 (55.8)
>20 mm 1592 (42.0) 6081 (44.9) 7673 (44.2)
†Missing 151 referral source. Missing 544 tumor size. n (%).
‡Tumor size is based on histopathology report.
ACT, Australian Capital Territory; DCIS, ductal carcinoma in situ; NSW, New South Wales; NT, Northern Territory; NZ, New Zealand; QLD, Queensland; SA, South
Australia; TAS, Tasmania; VIC, Victoria; WA, Western Australia.
Fig 3. Surgical procedures conducted among women with ductal
carcinoma in situ (DCIS) from year 2007 to 2016. CS, breast-conserving
surgery; SNB, sentinel node biopsy. Mastectomy ; BCS ; Re-
excision ; Reconstruction ; SNB .
© 2021 The Authors.
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operating in both countries. However, DCIS was more common in
women 40–49 years in New Zealand, and more common in women
70–79 years in Australia, consistent with the different policies on
age groups targeted for screening (45–69 vs. 50–74).
Management of DCIS in Australia and New Zealand appears to
have been stable over the years 2007–2016, with no major changes
in surgery, including axillary surgery, or adjuvant therapy being
observed. BCS followed by radiation therapy was more common
than mastectomy, particularly in women over 50 years. In contrast,
mastectomy was the most common surgical procedure in women
younger than 40 years. Mastectomy was also more common among
women with larger tumors—for example, a tumor size greater than
20 mm more than doubled the chance of mastectomy—and among
women with high-grade DCIS. Breast reconstruction was per-
formed among 12.6% of the women, mainly among younger
women, and a trend of decreasing reconstruction with age was
observed. Around one-third of the women diagnosed with DCIS
had a SNB (36.0%), with a slight increase in SNB rate over time,
accompanied by a slight decrease in the rate of ALND. SNB was
associated with type of surgery, with more women who were
treated with mastectomy receiving a SNB (71.2%) compared to
women receiving BCS (18.0% had SNB). These temporal trends
were not altered when adjusting for age, referral source, histological
grade, and menopausal status.
Findings in context
Most of the findings are expected and in line with current best sur-
gical practice. BCS followed by radiation therapy has become more
common than mastectomy, to minimize surgical intervention with
equally good outcomes.17 BCS gives a better cosmetic outcome,
but total mastectomy may be needed for multifocal or widespread
DCIS.14,18 International studies, as well as the previous study
conducted in this population, have reported similar trends, with
BCS followed by radiotherapy as the most common treatment
approach.5,7,14,19
Younger women have an increased risk of a second invasive
event of breast cancer than older women with DCIS.19,20 A higher
percentage among younger women could be expected to have a
more extensive disease, since they are below screening age and
most likely detected outside of screening. The treatment of DCIS
among younger women has tended to include more intensive sur-
gery such as total mastectomy and in some prophylactic contralat-
eral mastectomy.19 However, the long-term mortality rates of these
younger women do not indicate an improved prognosis following
the more extensive treatments, compared to BCS with adjuvant
therapy.19
Mastectomy is usually selected as a treatment when DCIS
appears multifocal or large,21 indicating more extensive or wide-
spread disease.4 Our findings accord with this. While size and grade
have been associated with treatment decision, these indicators do
not perfectly correlate with whether DCIS will advance to an inva-
sive disease or not. Further research on the biology of DCIS, bio-
logical markers, and gene profiling of DCIS pathology will
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reflect current practice, the BQA does not record these biological
markers, and this will be important in the future.
Given that these cases represent pure DCIS, and DCIS would not
be expected to have metastasized to the axillary nodes,22 SNB use
seems high. However, this may have been done to obviate the need
for a separate axillary procedure, for example, where there is risk of
underestimation of invasive disease at core-needle biopsy,23 or where
a subsequent axillary surgery may not be feasible, for example, BCS
with synchronous oncoplastic procedure. In the previous study
looking at the treatment trends in Australia and New Zealand, 6.5%
had a SNB alone, and 23.3% underwent some form of axillary proce-
dure.14 In our study, the proportion of women who had SNB is much
higher compared to the previous study; however, the number of
women who had axillary dissection has decreased. High rates of
SNB use for women with pure DCIS have also been found in other
countries, (54% in Denmark, 64% in Turkey) and similarly the
appropriateness of its use has been questioned.24,25
The use of SNB for DCIS treatment may have been appropriate
for some patients; we note that current guidelines for the manage-
ment of women with pure DCIS specify reasons for considering
SNB for DCIS as planned mastectomy, or when the risk of finding
an invasive component at excision surgery is estimated to be high
(extensive high-grade DCIS, palpable tumor/mass forming DCIS,
and/or microinvasion is suspected in biopsy).22,23,26,27 In our study,
44.9% of women presenting with a high-grade DCIS as well as
53.3% of women presenting with a DCIS tumor greater than
20 mm, had a SNB. In these cases, where the risk of finding inva-
sive disease is expected to be higher, a SNB might be an appropri-
ate management. Yet 19.6% of low-grade, 29.8% of intermediate-
grade, and 23.2% of DCIS cases with a tumor size less than 20 mm
had SNB. The appropriateness of conducting a SNB in these latter
cases is unclear (Table 3).
The benefit of a SNB during the initial surgery is that the woman
will not require a second surgical procedure, if an invasive
component is found in the excised tissue. In our study, 18.0% of
the women who had a BCS also had a SNB which may represent
overtreatment of a condition which often does not progress, thus
causing unnecessary intervention with potential harm. Even though
complications following SNB seem to be rare, ranging between
0.1% and 8.6% of women affected, they include axillary wound
infection, axillary seroma, axillary hematoma, axillary paresthesia,
decreased upper extremity motion, and lymphedema.28 The preva-
lence of SNB use among women when it is not indicated should be
monitored so guidelines and practice better align.
Strengths and limitations
The large sample size and long timeframe makes our study well
powered to detect changes in practice. Even though this database
represents the largest record of DCIS management in Australia and
New Zealand, the capture rate of 60% of self-reporting breast sur-
geons who are members of specialist society is a limitation. The
practice of surgeons not submitting cases for audit through
the BQA may differ.
Consensus management guidelines may lag behind contemporary
practice or even fail to make an impact on current therapeutics. This
overview is an important assessment of the state of DCIS treatment
in Australia and New Zealand. Perhaps, as it largely reflects the
work of a group of sub-specialists committed to audit, it may pre-
sent “best practice,” acknowledging a potential selection bias
toward better outcomes.
Implications for practice and research
There remains a need for education and promulgation of practice
guidelines as, even among subspecialist surgeons committed to
quality assurance and best practice, there may be over-treatment.
Over-diagnosis is a risk in this condition and there remains a need
to inform treating specialists about the opportunities to deescalate
Table 3 Ten years of surgical procedures by age, histology, menopausal status and tumor size
Mastectomy,
n (%)






SNB, n (%) ALND, n (%)
Age (p) <0.0001 <0.0001 <0.0001 0.0023 <0.0001 <0.0001 <0.0001
15–39 310 (62.4) 210 (42.3) 103 (20.7) 91 (18.3) 180 (36.2) 268 (53.9) 42 (8.5)
40–49 1385 (46.0) 1772 (58.9) 419 (13.9) 568 (18.9) 764 (25.4) 1273 (42.3) 134 (4.5)
50–59 1951 (34.8) 3771 (67.2) 651 (11.6) 1036 (18.5) 831 (14.8) 1957 (34.9) 199 (3.6)
60–69 1835 (31.9) 4016 (69.7) 646 (11.2) 1079 (18.7) 416 (7.2) 1955 (33.9) 201 (3.5)
70–74 538 (33.3) 1111 (68.8) 207 (12.8) 286 (17.7) 41 (2.5) 525 (32.5) 67 (4.2)
75–100 535 (38.5) 829 (59.7) 170 (12.3) 195 (14.1) 20 (1.4) 467 (33.7) 87 (6.3)
Histological grade (p) <0.0001 <0.0001 <0.0001 0.8994 <0.0001 <0.0001 <0.0001
Low 510 (21.8) 1666 (71.3) 498 (21.3) 435 (18.6) 172 (7.4) 459 (19.6) 58 (2.5)
Intermediate 1779 (31.7) 3880 (69.2) 768 (13.7) 1041 (18.6) 668 (11.9) 1672 (29.8) 179 (3.2)
High 4055 (44.3) 5694 (62.3) 798 (8.7) 1675 (18.3) 1353 (14.8) 4108 (44.9) 458 (5.0)
Menopausal status (p) <0.0001 <0.0001 <0.0001 0.8706 <0.0001 <0.0001 0.1631
Premenopausal 1728 (46.7) 2132 (57.6) 534 (14.4) 686 (18.5) 982 (26.5) 1581 (42.7) 168 (4.5)
Postmenopausal 4134 (33.4) 8421 (68.1) 1442 (11.7) 2252 (18.2) 966 (7.8) 4177 (33.8) 484 (3.9)
Perimenopausal 586 (37.5) 1006 (64.3) 207(13.2) 281 (18.0) 269 (17.2) 5 95 (38.0) 71 (4.5)
Tumor size† (p) <0.0001 <0.0001 0.0003 <0.0001 <0.0001 <0.0001 <0.0001
≤20 mm 1940 (20.1) 7237 (74.9) 1267 (13.1) 1560 (16.1) 578 (6.0) 2239 (23.2) 264 (2.7)
>20 mm 4453 (58.0) 4206 (54.8) 865 (11.3) 1638 (21.4) 1642 (21.4) 4087 (53.3) 436 (5.7)
†Tumor size is based on histopathology report.
ALND, axillary lymph node dissection; BCS, breast conserving surgery; SNB, sentinel node biopsy.
© 2021 The Authors.
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management. The path to de-escalation is difficult, as often over-
treatment is preferred in the absence of evidence to contrary. Cur-
rently, only 0.4% of women with DCIS in Australia and
New Zealand do not undergo surgery; this rate may be influenced
in the future by the results of the ongoing trials.
Biological markers and gene profiling of DCIS pathology will
increasingly inform decisions about management. The inclusion
of biological markers in the BQA or future registry should be
encouraged.
The management of DCIS has been essentially stable for
10 years. There have been modest increases in the use of recon-
struction and adjuvant therapy. This relative stability may be in part
because DCIS is a condition where practice changing evidence
requires long-term follow-up. Audits of surgical activity, such as
the BQA, are a useful tool to promote self-assessment against best-
practice. However, we would advocate for a formal bi-national reg-
istry to link existing databases and assess a range of DCIS therapy
for efficacy, cost–benefit, and patient satisfaction.
Conclusion
The management of women with DCIS does not seem to have
changed markedly during the past decade, but the potential for less
invasive treatments should be investigated. Clearer guidelines are
required into the appropriateness of SNBs in women with pure
DCIS. Further investigation of compliance of treatment with guide-
lines for management of DCIS is recommended both in Australia,
New Zealand, and internationally.
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